Aquestive Therapeutics, Inc.
NASDAQ:AQSTDrug Manufacturers - Specialty & Generic
+$0.23 today
- Market cap
- $475.10M
- Beta
- 1.45
- P/E (TTM)
- -8.3
- EPS (TTM)
- -$0.56
Volume 1.80M
Average 1.51M
AQST Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
Aquestive Therapeutics, Inc.NASDAQ: AQST
Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026
Other income / expenses remains negative
Q1 FY2026 other income / expenses was -$3.85M, compared with -$3.57M a year earlier. Trailing-twelve-month other income / expenses was -$13.02M.
Context
- Other income / expenses amounted to 31.7% of revenue in FY2025, up 8.5 pp from a year earlier.
- Other income / expenses increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly other income / expenses holds near -$3.85M or moves back toward the trailing-twelve-month quarterly average of -$3.26M.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- (14.13M) USD
- Year-over-year change
- -5.6%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (14.13M) | -5.6% |
| FY2024 | 2024-12-31 | (13.38M) | -278.9% |
| FY2023 | 2023-12-31 | 7.48M | +160.6% |
| FY2022 | 2022-12-31 | (12.34M) | +65.6% |
| FY2021 | 2021-12-31 | (35.86M) | — |
Other Income / Expenses vs competitors
How AQST compares with its peers on the latest reported figures
- AQST's LTM Mar 2026 other income / expenses of -$13.02M is the 6th highest of the 10 companies compared; the peer median is -$11.65M.
- Its year-over-year change of +0.4% is the 5th highest of 10, against a peer median of -6.0%.
- Other income / expenses amounts to 25.9% of revenue for AQST, versus a peer median of 4.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $182.15M | +5325.1% | +79.3% | 148.9% | |
| LTM Mar 2026 | $10.66M | -47.6% | +36.1% | 4.9% | |
| LTM Mar 2026 | -$2.18K | +95.7% | — | 0.0% | |
| LTM Mar 2026 | -$3.19M | -139.5% | — | 4.9% | |
| LTM Jun 2026 | -$11.65M | -164.6% | — | 1.4% | |
| LTM Mar 2026 | -$13.02M | +0.4% | — | 25.9% | |
| LTM Mar 2026 | -$13.93M | +36.6% | — | 1.9% | |
| LTM Mar 2026 | -$23.89M | +5.0% | — | 7.6% | |
| LTM Sep 2026 | -$52.91M | -224.7% | — | 3.0% | |
| LTM Mar 2026 | -$81.68M | -6.0% | — | 10.3% | |
| Peer median (excluding AQST) | -$11.65M | -6.0% | +57.7% | 4.9% | |
Competitors are the stored peer set for AQST. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 50.83M | 47.68M | 50.58M | 57.56M | 44.55M |
| Cost of Revenue | 14.99M | 19.39M | 20.83M | 17.87M | 17.15M |
| Gross Profit | 35.84M | 28.29M | 29.75M | 39.69M | 27.39M |
| Gross Margin | 70.5% | 59.3% | 58.8% | 69.0% | 61.5% |
| Research & Development | 17.05M | 17.48M | 13.1M | 20.28M | 17.19M |
| Selling, General & Admin | 53.48M | 52.88M | 31.75M | 50.18M | 79.85M |
| Operating Expenses | 70.52M | 70.36M | 44.85M | 70.46M | 97.04M |
| Depreciation & Amortization | 2.96M | 2.39M | 1.35M | 718K | 559K |
| EBITDA | (45.11M) | (39.58M) | 1.18M | (26.62M) | (66.13M) |
| EBITDA Margin | -88.8% | -83.0% | 2.3% | -46.2% | -148.4% |
| Operating Income | (34.68M) | (42.07M) | (15.1M) | (30.77M) | (69.65M) |
| Operating Margin | -68.2% | -88.2% | -29.9% | -53.5% | -156.4% |
| Interest Income | 423K | 99K | 16.32M | 3.44M | 0 |
| Interest Expense | 22.46M | 12.44M | 7.46M | 16.82M | 17.1M |
| Other Income / Expenses | (35.86M) | (12.34M) | 7.48M | (13.38M) | (14.13M) |
| Income Before Tax | (70.54M) | (54.41M) | (7.63M) | (44.15M) | (83.78M) |
| Pre-Tax Margin | -138.8% | -114.1% | -15.1% | -76.7% | -188.1% |
| Income Tax Expense | 0 | 0 | 245K | (14K) | 0 |
| Net Income | (70.54M) | (54.41M) | (7.87M) | (44.14M) | (83.78M) |
| Net Margin | -138.8% | -114.1% | -15.6% | -76.7% | -188.1% |
| EPS (Basic) | (1.85) | (1.12) | (0.13) | (0.51) | (0.76) |
| EPS (Diluted) | (1.85) | (1.12) | (0.13) | (0.51) | (0.76) |
| Weighted Avg Shares | 38.08M | 48.73M | 61.26M | 86.73M | 121.97M |
| Weighted Avg Shares (Diluted) | 38.08M | 48.73M | 61.26M | 86.73M | 121.97M |
Aquestive Therapeutics, Inc.
NASDAQ:AQST
Intrinsic Alpha fair value
Locked
Current Price
$3.78
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.